Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Dig Liver Dis
; 53(3): 277-282, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-1009433
ABSTRACT
BACKGROUND:
Patients receiving biologic therapies are at risk for viral infections. This study investigated the impact of the SARS-CoV-2 infection and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD) treated with biologic drugs.METHODS:
Information on demography, co-morbidities, clinical data regarding IBD, symptoms suggestive of the SARS-CoV-2 infection, close contacts with SARS-CoV-2 positive patients, hospitalization, and therapies administered for COVID-19 was collected for all patients who were being treated with biologic drugs. All patients underwent SARS-CoV-2 antibody testing.RESULTS:
Two hundred and fifty-nine patients (27 children) with a mean age of 42.2⯱â¯16.7 years (range 9 - 88) and a mean duration of disease of 13.4⯱â¯10 years (range 0.2 - 49) were enrolled. One hundred four patients (40.2%) had ulcerative colitis, and 155 (59.8%) had Crohn's disease. About the therapy 62 patients were receiving infliximab, 89 adalimumab, 20 golimumab, 57 vedolizumab, 27 ustekinumab, 1 thalidomide, and 3 an experimental compound. The mean Charlson Comorbidity Index was 2. Thirty-two patients (12.3%) reported respiratory symptoms, and 2 of them were hospitalized (0.77%). Two patients resulted positive for IgG against SARS-CoV-2 (0.77%).CONCLUSIONS:
In patients with IBD, treatment with biologic drug does not represent a risk factor for the SARS-CoV-2 infection.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biological Products
/
Gastrointestinal Agents
/
Inflammatory Bowel Diseases
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Country/Region as subject:
Europa
Language:
English
Journal:
Dig Liver Dis
Journal subject:
Gastroenterology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS